Backed by five pharma giants and a crew of Penn superstars, a startup uses mRNA to create in vivo CAR-T — with a pro at the helm
Earlier this year, Jonathan Epstein and other scientists at Penn published a paper in Science that spelled out the intriguing results of a mouse study. Using CD-5 targeted lipid nanoparticles, the tiny vehicles used to carry messenger RNA, they were able to reprogram T lymphocytes into CAR-Ts in vivo, in the body. Trained to recognize fibrotic cells specifically in the heart, the scientists involved were able to restore cardiac function in mice.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.